The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Real-world outcomes of DVd in myeloma at first relapse and its role in the evolving landscape
Dean Smith, BA(Hons), MBBS, MRCP, FRCPath, MD(Res), Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses findings from the largest real-world study to date evaluating daratumumab, bortezomib, and dexamethasone (DVd) in patients with multiple myeloma at first relapse in the UK. Dr Smith explains that time to next treatment was shorter in patients with prior bortezomib exposure but was not significantly affected by prior lenalidomide or autologous stem cell transplantation. He highlights DVd as an effective and well-tolerated option for older patients and those ineligible for or who do not wish to receive immunotherapy. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
